LAVA Therapeutics (NASDAQ:LVTX) Stock Price Up 8%

LAVA Therapeutics (NASDAQ:LVTXGet Free Report)’s share price traded up 8% during mid-day trading on Monday . The stock traded as high as $2.53 and last traded at $2.44. 76,769 shares traded hands during mid-day trading, a decline of 93% from the average session volume of 1,111,030 shares. The stock had previously closed at $2.26.

Analyst Upgrades and Downgrades

Separately, HC Wainwright reaffirmed a “buy” rating and set a $6.00 price target on shares of LAVA Therapeutics in a report on Thursday, March 21st.

Check Out Our Latest Analysis on LVTX

LAVA Therapeutics Stock Down 0.9 %

The firm has a market capitalization of $58.56 million, a PE ratio of -2.14 and a beta of 0.59. The company has a debt-to-equity ratio of 0.01, a current ratio of 7.42 and a quick ratio of 7.42. The company has a 50-day moving average price of $2.84 and a 200 day moving average price of $2.27.

LAVA Therapeutics (NASDAQ:LVTXGet Free Report) last posted its quarterly earnings results on Wednesday, March 20th. The company reported ($0.24) earnings per share for the quarter, missing the consensus estimate of $0.16 by ($0.40). The business had revenue of $0.35 million during the quarter, compared to the consensus estimate of $25.00 million. LAVA Therapeutics had a negative return on equity of 51.90% and a negative net margin of 228.02%. Analysts forecast that LAVA Therapeutics will post -1.3 earnings per share for the current year.

Hedge Funds Weigh In On LAVA Therapeutics

A hedge fund recently bought a new stake in LAVA Therapeutics stock. Pathway Financial Advisors LLC bought a new stake in shares of LAVA Therapeutics (NASDAQ:LVTXFree Report) in the first quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor bought 14,000 shares of the company’s stock, valued at approximately $47,000.

About LAVA Therapeutics

(Get Free Report)

LAVA Therapeutics N.V., a clinical-stage immuno-oncology company, focuses on developing cancer treatments. The company through its Gammabody platform, develops a portfolio of novel bispecific antibodies to engage and leverage the potency and precision of gamma delta T cells to elicit an anti-tumor immune response and enhance outcomes for cancer patients.

Featured Articles

Receive News & Ratings for LAVA Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for LAVA Therapeutics and related companies with's FREE daily email newsletter.